Skip to main content
Last Updated
Case Status
In the Matter of Medtronic plc, a public limited company; Medtronic, Inc., a corporation; and Intersect ENT, Inc., a corporation
FTC Matter/File Number
Docket Number
Enforcement Type
Part 2 Consents

Case Summary

The Federal Trade Commission required Medtronic, Inc. to divest a key subsidiary of Intersect ENT, Inc. as a condition of acquiring Intersect. Under the FTC consent decree, Instersect’s Fiagon subsidiary, which makes ear, nose, and throat navigation systems and balloon sinus dilation products, will be sold to Hemostasis, LLC. According to the complaint, without this divestiture, the acquisition would pose a threat to future competition in the United States for both ENT navigation systems and balloon sinus dilation products. On June 30, 2022, the Commission announced the final consent agreement in this matter.